The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Mapping and predicting mortality from systemic sclerosis
Elhaï, M., Meune, C., Boubaya, M., Avouac, J., HACHULLA, E., Balbir‐Gurman, A., Riemekasten, G., Airò, P., Joven, B. E., Vettori, S., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211448 · Cited by 695
Self-citationWollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
Khanna, D., Furst, D. E., Clements, P. J., Allanore, Y., Baron, M. G., Czirjak, L., Distler, O., Foeldvari, I., Kuwana, M., Matucci‐Cerinic, M., et al. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000231 · Cited by 551
Self-citationClements, P., Lachenbruch, P. A., Seibold, J. R., Zee, B. C.-Y., Steen, V. D., Brennan, P., Silman, A. J., Allegar, N. E., Varga, J., & Massa, M. C. (1993) · PubMed · Cited by 449
Angiogenic and angiostatic factors in the molecular control of angiogenesis.
Distler, J. H. W., Hirth, A., Kurowska‐Stolarska, M., Gay, R. E., Gay, S., & Distler, O. (2003) · PubMed · Cited by 398
Self-citationGoh, N. S. L., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40130 · Cited by 354
Self-citationHostettler, K., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., et al. (2014) · Respiratory Research · doi:10.1186/s12931-014-0157-3 · Cited by 268
Jaeger, V. K., Wirz, E. G., Allanore, Y., Roßbach, P., Riemekasten, G., HACHULLA, E., Distler, O., Airò, P., Carreira, P. E., Balbir‐Gurman, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163894 · Cited by 266
Self-citationHsu, E., Shi, H., Jordan, R. M., Lyons‐Weiler, J., Pilewski, J. M., & Feghali‐Bostwick, C. A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30159 · Cited by 227
Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207109 · Cited by 196
Self-citationHuang, J., Maier, C., Zhang, Y., Soare, A., Dees, C., Beyer, C., Steffen, U., Chen, C., Distler, O., Schett, G. A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210823 · Cited by 191
Self-citationAssassi, S., Sharif, R., Lasky, R. E., McNearney, T. A., Estrada-Y-Martin, R. M., Draeger, H. T., Nair, D. K., Fritzler, M. J., Reveille, J. D., Arnett, F. C., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3125 · Cited by 180
Self-citationLam, A. P., Flozak, A. S., Russell, S., Wei, J., Jain, M., Mutlu, G. M., Budinger, G. R. S., Feghali‐Bostwick, C. A., Varga, J., & Gottardi, C. J. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0113oc · Cited by 156
Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study
Khanna, D., Furst, D. E., Hays, R. D., Park, G. S., Wong, W. K., Seibold, J. R., Mayes, M. D., White, B., Wigley, F. F., Weisman, M. H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.050187 · Cited by 151
Self-citationEffects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 135
Hinchcliff, M., Beaumont, J. L., Thavarajah, K., Varga, J., Chung, A. H., Podlusky, S., Carns, M. A., Chang, R. W., & Cella, D. F. (2011) · Arthritis Care & Research · doi:10.1002/acr.20591 · Cited by 134
Pope, J. E. (2011) · Arthritis Care & Research · doi:10.1002/acr.20598 · Cited by 129
Frantz, C., Avouac, J., Distler, O., Amrouche, F., Godard, D., Kennedy, A. T., Connolly, K., Varga, J., Matucci‐Cerinic, M., & Allanore, Y. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.02.005 · Cited by 125
Self-citationGrowth Regulation in Scleroderma Fibroblasts: Increased Response to Transforming Growth Factor-β1
Kikuchi, K., Kadono, T., Ihn, H., Sato, S., Igarashi, A., Nakagawa, H., Tamaki, K., & Takehara, K. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12313452 · Cited by 97
Redente, E. F., Aguilar, M., Black, B. P., Edelman, B., Bahadur, A. N., Humphries, S. M., Lynch, D. A., Wollin, L., & Riches, D. W. H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00304.2017 · Cited by 88
Moore, O. A., Proudman, S., Goh, N. S. L., Corte, T. J., Rouse, H. C., Hennessy, O. F., Morrisroe, K., Thakkar, V., Sahhar, J., Roddy, J., et al. (2015) · PubMed · Cited by 78
Distler, O., Brown, K. K., Distler, J. H. W., Assassi, S., Maher, T. M., Cottin, V., Varga, J., Coeck, C., Gahlemann, M., Sauter, W., et al. (2017) · PubMed · Cited by 74
Self-citationHumanistic and cost burden of systemic sclerosis: A review of the literature
Fischer, A., Zimovetz, E. A., Ling, C. S., Esser, D., & Schoof, N. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.010 · Cited by 60
Self-citationSwigris, J. J., Wilson, H., Esser, D., Conoscenti, C., Stansen, W., Leidy, N. K., & Brown, K. K. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000278 · Cited by 54
Khanna, D., Clements, P. J., Volkmann, E. R., Wilhalme, H. M., Tseng, C., Furst, D. E., Roth, M. D., Distler, O., & Tashkin, D. P. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1809-y · Cited by 52
Self-citationWollin, L., Distler, J. H. W., Denton, C. P., & Gahlemann, M. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319841842 · Cited by 46
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationTocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J. G., Kim, G., Kuwana, M., Allanore, Y., Matucci‐Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 688
Self-citationVolkmann, E. R., Andréasson, K., & Smith, V. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 653
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Self-citationEvasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 642
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
